UNSPSC 51123120: Transcainide

This classification denotes an antiarrhythmic agent with the molecular formula C22H35N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5VSP2X37QG, chemically known as 4-piperidinecarboxamide, 4-(dimethylamino)-n-(2,6-dimethylphenyl)-1-(2-hydroxycyclohexyl)-, trans-(+-)- but more generally known as transcainide, which bears US NIH Compound Identifier 68608. European Medicines Agency schedules Transcainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11216MIG.

UNSPSC 51123120 Transcainide is a Commodity code covering pharmaceutical active ingredients and finished medications purchased by state and local health agencies, fire departments, and public health programs. The recent solicitation activity shows state and local governments buying Advanced Life Support Medications (including vasopressors, antiarrhythmics, and emergency injectables), generic multi-source pharmaceuticals through cooperative purchasing vehicles, and exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include municipal fire rescue departments (Tampa Fire Rescue via the City of Tampa's Purchasing Department), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local facilities across multiple states including Oregon and Minnesota). The work spans emergency medical supply procurement, generic pharmaceutical contracting at scale, and strategic procurement infrastructure redesign to improve cost management and supply chain efficiency.

Activity is concentrated in the South (Florida, Texas) and Upper Midwest (Minnesota, Oregon). The City of Tampa issued an IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026, with an estimated contract value of $40,000.00) seeking Labetalol, Epinephrine, Adenosine, and Diltiazem for fire rescue use, with a one-year term plus renewal options and a Small Local Business Enterprise set-aside with a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and wholesaler channels. MMCAP, administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with contract effectiveness July 1, 2026, weighted evaluation emphasizing price competitiveness (75 percent), and a two-year initial term with optional extensions.